ds-6000a
mAbexperimentalADC
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 25, 2021 (NCT04707248)
Timeline
Indications
Mechanism of action
- Cytochrome P450 17A1INHIBITOR
CYP17A1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Payload
- DXd
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095329 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07242469 | Phase 1 | Dec 18, 2025 | Merck |
| NCT06780098 | Phase 2 | May 23, 2025 | Daiichi Sankyo, Merck |
| NCT06780085 | Phase 2 | May 13, 2025 | Daiichi Sankyo, Merck |
| NCT06864169 | Phase 2 | Apr 9, 2025 | Daiichi Sankyo, Merck |
| NCT06843447 | Phase 1/Phase 2 (Phase 2) | Mar 27, 2025 | Daiichi Sankyo, Merck |
| NCT06660654 | Phase 2 | Dec 31, 2024 | Daiichi Sankyo, Merck |
| NCT06161025 | Phase 2/Phase 3 (Phase 3) | Feb 29, 2024 | Daiichi Sankyo, Merck |
| NCT04707248 | Phase 1 | Jan 25, 2021 | Daiichi Sankyo |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 7 | 3 | 3 | 2021 |
| Merck | For profit | 7 | 5 | 3 | 2024 |
2 organizations
Page 1 / 1